{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T19:43:17Z","timestamp":1786477397724,"version":"build-2736575974"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,4,10]],"date-time":"2018-04-10T00:00:00Z","timestamp":1523318400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Science and Technology Benefit Fund of Xiamen Technology Bureau","award":["3502Z20154027"],"award-info":[{"award-number":["3502Z20154027"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12933-018-0701-4","type":"journal-article","created":{"date-parts":[[2018,4,19]],"date-time":"2018-04-19T11:01:36Z","timestamp":1524135696000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Liraglutide suppresses non-esterified free fatty acids and soluble vascular cell adhesion molecule-1 compared with metformin in patients with recent-onset type 2 diabetes"],"prefix":"10.1186","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9874-3766","authenticated-orcid":false,"given":"Xiao-min","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-qiang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-fen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chan-chan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuan-mei","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,4,10]]},"reference":[{"key":"701_CR1","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1136\/bmj.321.7258.405","volume":"321","author":"IM Stratton","year":"2000","unstructured":"Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321:405\u201312.","journal-title":"BMJ"},{"key":"701_CR2","doi-asserted-by":"publisher","first-page":"434","DOI":"10.2337\/diacare.16.2.434","volume":"16","author":"J Stamler","year":"1993","unstructured":"Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-year cardiovascular mortality for men screened in the multiple risk factor intervention trial. Diabetes Care. 1993;16:434\u201344.","journal-title":"Diabetes Care"},{"key":"701_CR3","doi-asserted-by":"publisher","first-page":"S39","DOI":"10.1301\/nr.2007.jun.S39-S46","volume":"65","author":"WL Holland","year":"2007","unstructured":"Holland WL, Knotts TA, Chavez JA, Wang LP, Hoehn KL, Summers SA. Lipid mediators of insulin resistance. Nutr Rev. 2007;65:S39\u201346.","journal-title":"Nutr Rev"},{"key":"701_CR4","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1016\/S0140-6736(10)60408-4","volume":"375","author":"VT Samuel","year":"2010","unstructured":"Samuel VT, Petersen KF, Shulman GI. Lipid-induced insulin resistance: unravelling the mechanism. Lancet. 2010;375:2267\u201377.","journal-title":"Lancet"},{"key":"701_CR5","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s11892-006-0031-x","volume":"6","author":"G Boden","year":"2006","unstructured":"Boden G. Fatty acid-induced inflammation and insulin resistance in skeletal muscle and liver. Curr Diab Rep. 2006;6:177\u201381.","journal-title":"Curr Diab Rep."},{"key":"701_CR6","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1111\/j.1464-5491.2007.02186.x","volume":"24","author":"JP Wilding","year":"2007","unstructured":"Wilding JP. The importance of free fatty acids in the development of type 2 diabetes. Diabet Med. 2007;24:934\u201345.","journal-title":"Diabet Med"},{"issue":"4","key":"701_CR7","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1172\/JCI23354","volume":"116","author":"X Du","year":"2006","unstructured":"Du X, Edelstein D, Obici S, Higham N, Zou MH, Brownlee M. Insulin resistance reduces arterial prostacyclin synthase and eNOS activities by increasing endothelial fatty acid oxidation. J Clin Invest. 2006;116(4):1071\u201380.","journal-title":"J Clin Invest."},{"issue":"4","key":"701_CR8","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1111\/cns.12068","volume":"19","author":"HG Zhou","year":"2013","unstructured":"Zhou HG, Liu L, Zhang Y, Huang YY, Tao YH, Zhang S, et al. Glutathione prevents free fatty acids-induced oxidative stress and apoptosis in human brain vascular endothelial cells through Akt pathway. CNS Neurosci Ther. 2013;19(4):252\u201361.","journal-title":"CNS Neurosci Ther"},{"issue":"11","key":"701_CR9","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1002\/phar.1507","volume":"34","author":"JM Trujillo","year":"2014","unstructured":"Trujillo JM, Nuffer W. GLP-1 receptor agonists for type 2\u00a0diabetes\u00a0mellitus: recent developments and emerging agents. Pharmacotherapy. 2014;34(11):1174\u201386.","journal-title":"Pharmacotherapy."},{"issue":"12","key":"701_CR10","doi-asserted-by":"publisher","first-page":"3270","DOI":"10.2337\/dc14-0893","volume":"37","author":"R Retnakaran","year":"2014","unstructured":"Retnakaran R, Kramer CK, Choi H, Swaminathan B, Zinman B. Liraglutide and the preservation of pancreatic \u03b2-cell function in early type 2 diabetes: the LIBRA trial. Diabetes Care. 2014;37(12):3270\u20138.","journal-title":"Diabetes Care"},{"issue":"9","key":"701_CR11","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1177\/1535370214567614","volume":"240","author":"J Zheng","year":"2015","unstructured":"Zheng J, Chen T, Zhu Y, Li HQ, Deng XL, Wang QH, Zhang JY, Chen LL. Liraglutide prevents fast weight gain and \u03b2-cell dysfunction in male catch-up growth rats. Exp Biol Med (Maywood). 2015;240(9):1165\u201376.","journal-title":"Exp Biol Med (Maywood)."},{"issue":"1","key":"701_CR12","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s12933-016-0341-5","volume":"15","author":"L Masmiquel","year":"2016","unstructured":"Masmiquel L, Leiter LA, Vidal J, Bain S, Petrie J, Franek E, et al. LEADER 5: prevalence and cardiometabolic impact of obesity in cardiovascular high-risk patients with type 2 diabetes mellitus: baseline global data from the LEADER trial. Cardiovasc Diabetol. 2016;15(1):29.","journal-title":"Cardiovasc Diabetol."},{"issue":"4","key":"701_CR13","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1111\/j.1463-1326.2010.01345.x","volume":"13","author":"P Anagnostis","year":"2011","unstructured":"Anagnostis P, Athyros VG, Adamidou F, Panagiotou A, Kita M, Karagiannis A, Mikhailidis DP. Glucagon-like peptide-1-based therapies and cardiovascular disease: looking beyond glycaemic control. Diabetes Obes Metab. 2011;13(4):302\u201312.","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"701_CR14","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1186\/s12933-017-0626-3","volume":"16","author":"R Bruen","year":"2017","unstructured":"Bruen R, Curley S, Kajani S, Crean D, O\u2019Reilly ME, Lucitt MB, Godson CG, McGillicuddy FC, Belton O. Liraglutide\u00a0dictates macrophage phenotype in apolipoprotein E null mice during early atherosclerosis. Cardiovasc Diabetol. 2017;16(1):143.","journal-title":"Cardiovasc Diabetol."},{"issue":"5","key":"701_CR15","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1007\/s10557-014-6539-4","volume":"28","author":"Y Dai","year":"2014","unstructured":"Dai Y, Mehta JL, Chen M. Glucagon-like peptide-1 receptor agonist\u00a0liraglutide\u00a0inhibits endothelin-1 in endothelial cell by repressing nuclear factor-kappa B activation. Cardiovasc Drugs Ther. 2014;28(5):425\u201332.","journal-title":"Cardiovasc Drugs Ther"},{"issue":"11","key":"701_CR16","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1055\/s-0043-110603","volume":"67","author":"T Hiramatsu","year":"2017","unstructured":"Hiramatsu T, Ozeki A, Ishikawa H, Furuta S. Long term effects of\u00a0liraglutide\u00a0in japanese patients with type 2 diabetes among the subgroups with different renal functions: results of 2-year prospective study. Drug Res (Stuttg). 2017;67(11):640\u20136.","journal-title":"Drug Res (Stuttg)."},{"issue":"3","key":"701_CR17","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.numecd.2009.09.003","volume":"21","author":"L Spadaro","year":"2011","unstructured":"Spadaro L, Alagona C, Palermo F, Piro S, Calanna S, Parrinello G, Purrello F, Rabuazzo AM. Early phase insulin secretion is increased in subjects with normal fasting glucose and metabolic syndrome: a premature feature of beta-cell dysfunction. Nutr Metab Cardiovasc Dis. 2011;21(3):206\u201312.","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"2","key":"701_CR18","doi-asserted-by":"publisher","first-page":"245","DOI":"10.2337\/diacare.18.2.245","volume":"18","author":"DB Allison","year":"1995","unstructured":"Allison DB, Paultre F, Maggio C, Mezzitis N, Pi-Sunyer X. The use of areas under curves in diabetes research. Diabetes Care. 1995;18(2):245\u201350.","journal-title":"Diabetes Care"},{"key":"701_CR19","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/0167-4889(92)90015-4","volume":"1175","author":"N Loirdighi","year":"1992","unstructured":"Loirdighi N, Menard D, Levy E. Insulin decreases chylomicron production in human fetal small intestine. Biochim Biophys Acta. 1992;1175:100\u20136.","journal-title":"Biochim Biophys Acta"},{"key":"701_CR20","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1007\/s00125-005-0126-y","volume":"49","author":"JJ Meier","year":"2006","unstructured":"Meier JJ, Gethmann A, Gotze O, Gallwitz B, Holst JJ, Schmidt WE, Nauck MA. Glucagon-like peptide 1 abolishes the postprandial rise in triglyceride concentrations and lowers levels of nonesterified fatty acids in humans. Diabetologia. 2006;49:452\u20138.","journal-title":"Diabetologia."},{"key":"701_CR21","doi-asserted-by":"publisher","first-page":"580","DOI":"10.2337\/db09-1297","volume":"59","author":"M Pavlic","year":"2010","unstructured":"Pavlic M, Xiao C, Szeto L, Patterson BW, Lewis GF. Insulin acutely inhibits intestinal lipoprotein secretion in humans in part by suppressing plasma free fatty acids. Diabetes. 2010;59:580\u20137.","journal-title":"Diabetes"},{"key":"701_CR22","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1007\/s00125-009-1611-5","volume":"53","author":"J Hsieh","year":"2010","unstructured":"Hsieh J, Longuet C, Baker CL, Qin B, Federico LM, Drucker DJ, Adeli K. The glucagon-like peptide 1 receptor is essential for postprandial lipoprotein synthesis and secretion in hamsters and mice. Diabetologia. 2010;53:552\u201361.","journal-title":"Diabetologia"},{"key":"701_CR23","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.atherosclerosissup.2008.05.014","volume":"9","author":"K Cianflone","year":"2008","unstructured":"Cianflone K, Paglialunga S, Roy C. Intestinally derived lipids: metabolic regulation and consequences\u2013an overview. Atheroscler Suppl. 2008;9:63\u20138.","journal-title":"Atheroscler Suppl."},{"key":"701_CR24","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.atherosclerosis.2010.05.028","volume":"212","author":"EA Schwartz","year":"2010","unstructured":"Schwartz EA, Koska J, Mullin MP, Syoufi I, Schwenke DC, Reaven PD. Exenatide suppresses postprandial elevations in lipids and lipoproteins in individuals with impaired glucose tolerance and recent onset of type 2 diabetes mellitus. Atherosclerosis. 2010;212:217\u201322.","journal-title":"Atherosclerosis."},{"key":"701_CR25","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1172\/JCI111711","volume":"75","author":"CS Wang","year":"1985","unstructured":"Wang CS, McConathy WJ, Kloer HU, Alaupovic P. Modulation of lipoprotein lipase activity by apolipoproteins. Effect of apolipoprotein C-III. J Clin Invest. 1985;75:384\u201390.","journal-title":"J Clin Invest."},{"key":"701_CR26","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1161\/01.ATV.15.7.963","volume":"15","author":"V Clavey","year":"1995","unstructured":"Clavey V, Lestavel-Delattre S, Copin C, Bard JM, Fruchart JC. Modulation of lipoprotein B binding to the LDL receptor by exogenous lipids and apolipoproteins CI, CII, CIII, and E. Arterioscler Thromb Vasc Biol. 1995;15:963\u201371.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"701_CR27","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1007\/s00125-003-1207-4","volume":"46","author":"GC Yaney","year":"2003","unstructured":"Yaney GC, Corkey BE. Fatty acid metabolism and insulin secretion in pancreatic beta cells. Diabetologia. 2003;46:1297\u2013312.","journal-title":"Diabetologia"},{"issue":"1","key":"701_CR28","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1113\/jphysiol.2007.135871","volume":"583","author":"P Newsholme","year":"2007","unstructured":"Newsholme P, Haber EP, Hirabara SM, Rebelato ELO, Procopio J, Morgan D, et al. Diabetes associated cell stress and dysfunction: role of mitochondrial and nonmitochondrial ROS production and activity. J Physiol. 2007;583(1):9\u201324.","journal-title":"J Physiol"},{"issue":"1","key":"701_CR29","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.atherosclerosis.2015.07.003","volume":"242","author":"KT Teng","year":"2015","unstructured":"Teng KT, Chang CY, Kanthimathi MS, Tan AT, Nesaretnam K. Effects of amount and type of dietary fats on postprandial lipemia and thrombogenic markers in individuals with metabolic syndrome. Atherosclerosis. 2015;242(1):281\u20137.","journal-title":"Atherosclerosis."},{"issue":"5","key":"701_CR30","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1007\/s00125-002-0800-2","volume":"45","author":"HO Steinberg","year":"2002","unstructured":"Steinberg HO, Baron AD. Vascular function, insulin resistance and fatty acids. Diabetologia. 2002;45(5):623\u201334.","journal-title":"Diabetologia"},{"key":"701_CR31","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1186\/cc13733","volume":"18","author":"R Zonneveld","year":"2014","unstructured":"Zonneveld R, Martinelli R, Shapiro NI, Kuijpers TW, Plotz FB, Carman CV. Soluble adhesion molecules as markers for sepsis and the potential pathophysiological discrepancy in neonates, children and adults. Crit Care. 2014;18:204.","journal-title":"Crit Care"},{"issue":"8","key":"701_CR32","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1007\/s00125-013-2919-8","volume":"56","author":"MG Eupen van","year":"2013","unstructured":"van Eupen MG, Schram MT, Colhoun HM, Hanssen NM, Niessen HW, Tarnow L, et al. The methylglyoxal-derived AGE tetrahydropyrimidine is increased in plasma of individuals with type 1 diabetes mellitus and in atherosclerotic lesions and is associated with sVCAM-1. Diabetologia. 2013;56(8):1845\u201355.","journal-title":"Diabetologia"},{"key":"701_CR33","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/s12933-014-0138-3","volume":"13","author":"CS G\u00f6bl","year":"2014","unstructured":"G\u00f6bl CS, Bozkurt L, Yarragudi R, Prikoszovich T, Tura A, Pacini G, Koppensteiner R, Kautzky-Willer A. A Biomarkers of endothelial dysfunction in relation to impaired carbohydrate metabolism following pregnancy with gestational diabetes mellitus. Cardiovasc Diabetol. 2014;13:138.","journal-title":"Cardiovasc Diabetol."},{"issue":"19","key":"701_CR34","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1001\/jama.287.19.2570","volume":"287","author":"JA Beckman","year":"2002","unstructured":"Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA. 2002;287(19):2570\u201381.","journal-title":"JAMA"},{"issue":"1","key":"701_CR35","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1186\/s12933-016-0480-8","volume":"15","author":"M Rizzo","year":"2016","unstructured":"Rizzo M, Rizvi AA, Patti AM, Nikolic D, Giglio RV, Castellino G, et al. Liraglutide improves metabolic parameters and carotid intima-media thickness in diabetic patients with the metabolic syndrome: an 18-month prospective study. Cardiovasc Diabetol. 2016;15(1):162.","journal-title":"Cardiovasc Diabetol."},{"issue":"4","key":"701_CR36","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, et al. liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311\u201322.","journal-title":"N Engl J Med."},{"issue":"Suppl 1","key":"701_CR37","first-page":"S3","volume":"43","author":"B Verg\u00e8s","year":"2017","unstructured":"Verg\u00e8s B, Charbonnel B. After the LEADER trial and SUSTAIN-6, how do we explain the cardiovascular benefits of some GLP-1 receptor agonists? Diabetes Metab. 2017;43(Suppl 1):S3\u201312.","journal-title":"Diabetes Metab."},{"key":"701_CR38","doi-asserted-by":"publisher","first-page":"27186","DOI":"10.1074\/jbc.270.45.27186","volume":"270","author":"S Hawley","year":"1995","unstructured":"Hawley S, Selbert M, Goldstein E, Edelman A, Carling D, et al. 5\u2032-AMP activates the AMP-activated protein kinase cascade, and Ca2\u2009+\/calmodulin activates the calmodulin-dependent protein kinase I cascade, via three independent mechanisms. J Biol Chem. 1995;270:27186\u201391.","journal-title":"J Biol Chem"},{"issue":"5","key":"701_CR39","doi-asserted-by":"publisher","first-page":"e9755","DOI":"10.1371\/journal.pone.0097554","volume":"9","author":"NM Krasner","year":"2014","unstructured":"Krasner NM, Ido Y, Ruderman NB, Cacicedo JM. Glucagon-like peptide-1(GLP-1) analog liraglutide inhibits endothelial cell inflammation through a calcium and AMPK dependent mechanism. PLoS ONE. 2014;9(5):e9755.","journal-title":"PLoS ONE"},{"key":"701_CR40","doi-asserted-by":"publisher","first-page":"e2925","DOI":"10.1002\/dmrr.2925","volume":"33","author":"P Tomo Di","year":"2017","unstructured":"Di Tomo P, Lanuti P, Di Pietro N, Baldassarre MPA, Marchisio M, Pandolfi A, Consoli A, Formoso G. Liraglutide mitigates TNF-\u03b1 induced pro-atherogenic changes and microvesicle release in HUVEC from diabetic women. Diabetes Metab Res Rev. 2017;33:e2925.","journal-title":"Diabetes Metab Res Rev."},{"issue":"1","key":"701_CR41","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/s12933-017-0613-8","volume":"16","author":"S Ebtehaj","year":"2017","unstructured":"Ebtehaj S, Gruppen EG, Parvizi M, Tietge UJF, Dullaart RPF. The anti-inflammatory function of HDL is impaired in type 2 diabetes: role of hyperglycemia, paraoxonase-1 and low grade inflammation. Cardiovasc Diabetol. 2017;16(1):132.","journal-title":"Cardiovasc Diabetol."},{"issue":"6","key":"701_CR42","doi-asserted-by":"publisher","first-page":"E1209","DOI":"10.1152\/ajpendo.00237.2004","volume":"287","author":"T Nystrom","year":"2004","unstructured":"Nystrom T, Gutniak MK, Zhang Q, Zhang F, Holst JJ, et al. Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am J Physiol Endocrinol Metab. 2004;287(6):E1209\u201315.","journal-title":"Am J Physiol Endocrinol Metab."},{"issue":"1","key":"701_CR43","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s12868-016-0272-9","volume":"17","author":"PC Li","year":"2016","unstructured":"Li PC, Liu LF, Jou MJ, Wang HK. The GLP-1 receptor agonists exendin-4 and liraglutide alleviate oxidative stress and cognitive and\u00a0micturition deficits induced by middle cerebral artery occlusion in diabetic mice. BMC Neurosci. 2016;17(1):37.","journal-title":"BMC Neurosci."}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-018-0701-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12933-018-0701-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-018-0701-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,9]],"date-time":"2019-04-09T19:27:36Z","timestamp":1554838056000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-018-0701-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,10]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["701"],"URL":"https:\/\/doi.org\/10.1186\/s12933-018-0701-4","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,10]]},"assertion":[{"value":"5 February 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"53"}}